Vagus Nerve Stimulation for Rheumatoid Arthritis: What the Evidence Shows

Introduction: The Strongest Case for an Anti-Inflammatory Effect

Of all the conditions for which vagus nerve stimulation (VNS) has been proposed, rheumatoid arthritis (RA) has the most compelling biological story — and, as of 2026, the strongest clinical evidence. RA is an autoimmune disease in which the immune system attacks the lining of the joints, driven by inflammatory signalling molecules called cytokines. The vagus nerve, through a circuit known as the inflammatory reflex, can restrain the production of those very cytokines. That convergence made RA the natural proving ground for the idea that stimulating a nerve could treat an immune disease.

This article sets out what the evidence shows — including a landmark randomised trial — while keeping the result in proportion. The headline is genuinely positive by the standards of this field, but the effect is moderate rather than dramatic, the strongest data come from surgically implanted devices rather than the consumer ear-clips sold online, and VNS is being studied as an addition to standard care, not a replacement for it.

The Inflammatory Reflex: Why the Vagus Nerve Matters in RA

The scientific foundation here is unusually solid. In a landmark paper, Tracey (2002) described the "inflammatory reflex" — a neural circuit in which the vagus nerve senses inflammation in the body and, through its outgoing fibres, acts to suppress it. The downstream mechanism, the cholinergic anti-inflammatory pathway, operates partly through the spleen, where acetylcholine signalling on immune cells reduces the release of tumour necrosis factor (TNF) and other pro-inflammatory cytokines.

This matters for RA specifically because TNF is one of the principal drivers of the disease — so much so that anti-TNF biologic drugs revolutionised its treatment. If the vagus nerve can turn down TNF production through a built-in neural circuit, then stimulating it might, in principle, do some of the same work. This is the logic explored in depth in our article on VNS and inflammation, and RA is its clearest clinical test.

Early Proof of Concept: Koopman 2016

The first influential human evidence came from Koopman et al. (2016), published in the Proceedings of the National Academy of Sciences. In this open-label proof-of-concept study, 17 patients with RA received an implanted vagus nerve stimulator. The results were striking for an early study: stimulation reduced TNF production by patients' immune cells and produced significant improvements in disease activity, as measured by the standard DAS28 score. Tellingly, when stimulation was switched off, TNF production and disease activity worsened again — and improved once more when it was switched back on.

That on-off pattern was important because it suggested the effect was genuinely driven by the stimulation rather than by chance or expectation. But the study had no sham control and only a small number of patients, so while it was a powerful signal, it could not by itself establish efficacy. It set the stage for a properly controlled trial.

RESET-RA: The First Pivotal Trial

That trial has now reported. Tesser et al. (2026), published in Nature Medicine, presented RESET-RA — a randomised, double-blind, sham-controlled study of an implanted vagus nerve stimulation device (the SetPoint System) in 242 patients with RA who had not responded adequately to biologic or targeted synthetic disease-modifying drugs. This is the first pivotal-scale, sham-controlled trial of the approach, and its design is what gives it weight: neither patients nor assessors knew who was receiving active stimulation.

The trial met its primary endpoint. At three months, an ACR20 response — a standard 20% improvement in RA signs and symptoms — was achieved by 35.2% of the active-stimulation group versus 24.2% of the sham group (P = 0.0209). In the subsequent open-label phase, response rates rose further, to 52.8% at 12 months, and adverse events were similar between the active and sham groups.

This is a real, statistically significant result in a hard-to-treat population — and that is genuinely notable. But proportion matters:

The benefit, while real, was moderate. An 11-percentage-point difference over sham at the primary timepoint is a meaningful signal in refractory disease, but it is not the kind of dramatic effect that would displace existing therapies. RESET-RA establishes that the approach works better than sham — not that it is a cure.

The later 52.8% figure comes from the open-label phase, in which everyone knew they were receiving active treatment, so it cannot be compared with sham in the same way as the three-month result. The controlled comparison is the 35.2% versus 24.2% figure, and that is the number to anchor on.

What the Broader Review Evidence Shows

Beyond RA specifically, Lombo et al. (2025), in a systematic review in ACR Open Rheumatology, examined VNS across 12 clinical trials in autoimmune conditions (332 participants in total). The review found that VNS was associated with reduced release of pro-inflammatory cytokines — TNF, interleukin-1β, and interleukin-6 — in more than half of the studies, with the most consistent signal for the cytokines most relevant to RA.

The reviewers were careful, however, to note the limitations: small sample sizes, heterogeneous methods, and variation in how stimulation was delivered. The pattern is consistent with a genuine anti-inflammatory effect, but the certainty of the evidence remains moderate at best across the autoimmune field as a whole. RA is simply the area where it is strongest.

Invasive Versus Non-Invasive: A Crucial Distinction

This is the single most important caveat for anyone reading about VNS for RA. The strongest evidence — Koopman 2016 and RESET-RA — used surgically implanted vagus nerve stimulators placed during an operation. These are regulated medical devices used under specialist care, not the non-invasive ear-clip devices (transcutaneous auricular VNS, or taVNS) marketed directly to consumers.

Whether non-invasive taVNS can reproduce the anti-inflammatory effects seen with implanted devices in RA is, at present, an open and far less well-supported question. The convenience of a wearable ear device is obvious, but the trial evidence that has moved the needle in RA did not use one. Conflating the two would badly overstate what the consumer products have been shown to do.

What RESET-RA Does and Doesn't Prove

It is worth being precise about what a single pivotal trial establishes, because positive headlines tend to blur the line. RESET-RA shows, through a rigorous double-blind design, that an implanted vagus nerve device produced a real improvement over sham in people whose RA had not responded adequately to modern drugs. That moves vagus nerve stimulation from "biologically plausible" to "demonstrated better than placebo" — a step very few neuromodulation applications have achieved.

What it does not show matters just as much. The controlled effect was moderate — an 11-percentage-point ACR20 advantage at three months — so this is an additional option for refractory disease, not a first-line therapy or a replacement for disease-modifying drugs and biologics. The trial does not establish how durable the benefit is once the blinded phase ends, because the stronger 12-month numbers come from open-label follow-up in which everyone knew they were being treated. It does not identify which patients are most likely to respond. And it says nothing about whether non-invasive ear devices could do anything comparable, since it used a surgically implanted system — a distinction that cannot be assumed away.

In short, RESET-RA is a genuine proof that the approach beats sham in refractory RA, bounded by real limits on magnitude, durability, and generalisability. That is a stronger position than almost any other VNS application can claim — and still some distance from a settled, broadly applicable treatment.

Safety and Tolerability

Implanted VNS has a long safety record from its decades of use in epilepsy and depression. In RESET-RA, adverse events in the active group were comparable to sham, and the procedure-related risks are those of any minor implant surgery. Non-invasive taVNS, separately, is generally well tolerated, with mostly mild and transient side effects — as discussed in our review of the safety profile of VNS.

As always, tolerability is not the same as efficacy, and the safety of a device says nothing about whether it works for a given condition.

The Bottom Line

Rheumatoid arthritis is the strongest case yet made for vagus nerve stimulation as an anti-inflammatory treatment, and it now rests on more than mechanism alone:

- The biological rationale — the inflammatory reflex suppressing TNF — is well established (Tracey, 2002).
- An early proof-of-concept study showed an on-off effect on cytokines and disease activity (Koopman et al., 2016).
- A pivotal, sham-controlled trial met its primary endpoint, with a real but moderate benefit over sham (Tesser et al., 2026).
- Broader reviews support an anti-inflammatory signal while cautioning that the evidence is still limited (Lombo et al., 2025).

The honest summary is that this is a promising, genuinely evidence-backed approach for refractory RA — delivered, in the studies that matter, by an implanted device under specialist care. It is an addition to the treatment landscape, not a cure, and not something the consumer ear-clip evidence currently supports. Anyone with RA considering neuromodulation should discuss it with their rheumatologist rather than self-treating.

You can explore the underlying studies in our Evidence Database, where each trial is listed with its design and findings.

---

References

Koopman, F.A. et al. (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 113(29), 8284–8289.

Lombo, L.E. et al. (2025). Vagus nerve stimulation in autoimmune conditions: a systematic review. ACR Open Rheumatology, 7(12), e70137.

Tesser, J.R.P. et al. (2026). Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nature Medicine, 32(1), 369–378.

Tracey, K.J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859.